Drug Profile
IOG 101
Alternative Names: IOG-101Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator ioGenetics
- Class Antibacterials; Antibodies; Recombinant fusion proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA
- 29 Jul 2016 Preclinical trials in Staphylococcal infections in USA (unspecified route)